Exelixis Inc. Stock
Exelixis Inc. Stock
The Exelixis Inc. stock is trending slightly upwards today, with an increase of €0.15 (0.380%) compared to yesterday's price.
With 40 Buy predictions and not a single Sell prediction Exelixis Inc. is an absolute favorite of our community.
With a target price of 40 € there is a slightly positive potential of 1.16% for Exelixis Inc. compared to the current price of 39.54 €.
So far the community has only identified positive things for Exelixis Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 0.380% | 10.540% | 7.827% | 22.910% | 21.140% | 166.370% | 134.575% |
| Ironwood Pharmaceuticals | -0.740% | -9.459% | -4.965% | -37.383% | -36.190% | -76.716% | -72.653% |
| Novocure Ltd | -2.280% | 7.340% | 8.635% | -61.544% | -61.332% | -84.916% | -91.963% |
| Iovance Biotherapeutics Inc. | -0.280% | 11.832% | 10.644% | -66.564% | -65.306% | -57.442% | -94.118% |
Comments
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at TD Cowen from $44.00 to $51.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Morgan Stanley from $44.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is
Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly
